Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6414596 | 0.84 | CYP19A1 (0.49) | LMNASMN1; SMN2ALDH1A1GAAHTT | |
| SCHEMBL11214236 | 0.76 | LMNA (0.54) | LMNASMN1; SMN2ALDH1A1GAAHTT | |
| SCHEMBL6434742 | 0.76 | LMNA (0.54) | LMNASMN1; SMN2ALDH1A1GAAHTT | |
| SCHEMBL9701406 | 0.74 | SMN1; SMN2 (0.37) | LMNASMN1; SMN2ALDH1A1GAAHTT | |
| SCHEMBL11217085 | 0.72 | LMNA (0.53) | LMNASMN1; SMN2ALDH1A1GAAHTT | |
| SCHEMBL11213584 | 0.71 | LMNA (0.56) | LMNASMN1; SMN2ALDH1A1GAAHTT | |
| SCHEMBL8554586 | 0.70 | TSHR (0.40) | SMN1; SMN2GAAHPGDNPSR1 | |
| SCHEMBL25073933 | 0.70 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1GAAHTT | |
| SCHEMBL5278680 | 0.70 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1GAAHTT | |
| Diethylamine SCHEMBL9699242 | 0.70 | SMN1; SMN2 (0.45) | LMNASMN1; SMN2ALDH1A1GAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6932961-B1 | Oxazinocarbazoles for the treatment of CNS diseases | PHARMACIA & UPJOHN COMPANY (US) | 2005-08-23 | — | — | US | disclosed |
| EP-1495031-A1 | LABELED OXAZINOCARBAZOLES AS DIAGNOSTIC AGENTS | Pharmacia & Upjohn Company LLC (US) | 2005-01-12 | — | — | EP | disclosed |
| US-6821970-B2 | USEFUL FOR TREATING DISEASES WHEREIN MODULATION OF 5-HT ACTIVITY IS DESIRED; NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2004-11-23 | — | — | US | disclosed |
| WO-2003089438-A1 | LABELED OXAZINOCARBAZOLES AS DIAGNOSTIC AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2003-10-30 | — | — | WO | disclosed |
| EP-1200447-B1 | OXAZINOCARBAZOLES FOR THE TREATMENT OF CNS DISEASES | UPJOHN CO (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20020169317-A1 | Oxazinocarbazoles for the treatment of CNS diseases | TENBRINK RUTH ELIZABETH (US) | 2002-11-14 | — | — | US | disclosed |
| US-6448397-B1 | TREATING CENTRAL NERVOUS SYSTEM DISEASES WITH MODULATION OF 5-HT ACTIVITY; ADRENERGIC, DOPAMINERGIC, AND SEROTONERGIC NEUROTRANSMITTERS; PSYCHOSIS, PARAPHRENIA, DEPRESSION, MANIA, SCHIZOPHRENIA, ANXIETY, MIGRAINE HEADACHE, DRUG ADDICTION | PHARMACIA & UPJOHN COMPANY | 2002-09-10 | — | — | US | disclosed |
| EP-1200447-A1 | OXAZINOCARBAZOLES FOR THE TREATMENT OF CNS DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001009142-A1 | OXAZINOCARBAZOLES FOR THE TREATMENT OF CNS DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169317-A1 | Oxazinocarbazoles for the treatment of CNS diseases | HTR1B, TPH1, HTR7 | LMNA 3991/4885SMN1; SMN2 1199/4885ALDH1A1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.